A key Alzheimer’s drug has finally revealed its secret. Researchers discovered that lecanemab works by activating the brain’s immune cells—but only through a specific part of the antibody called the Fc fragment. This piece acts like a trigger, prompting microglia to clear harmful amyloid plaques. The finding could reshape how future Alzheimer’s therapies are designed.
View the full article